ORGS Stock Overview
A biotech company, focuses on cell and gene therapies worldwide. More details
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Orgenesis Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.22 |
52 Week High | US$10.80 |
52 Week Low | US$0.87 |
Beta | 1.32 |
11 Month Change | 1.88% |
3 Month Change | -83.21% |
1 Year Change | -75.55% |
33 Year Change | -96.46% |
5 Year Change | -96.08% |
Change since IPO | 224.24% |
Recent News & Updates
Recent updates
Orgenesis Inc.'s (NASDAQ:ORGS) Price Is Right But Growth Is Lacking After Shares Rocket 119%
Mar 04Orgenesis GAAP EPS of $0.22 beats by $0.24, revenue of $7.2M beats by $0.2M
Aug 16Orgenesis gets FDA IDE approval for Tissue Genesis Icellator COVID-19 study
May 06Orgenesis shares rise after Bambino Gesù Children's Hospital collaboration
Apr 30Orgenesis (NASDAQ:ORGS) Has Debt But No Earnings; Should You Worry?
Feb 05Shareholder Returns
ORGS | US Biotechs | US Market | |
---|---|---|---|
7D | 3.6% | 4.0% | 2.2% |
1Y | -75.6% | 18.3% | 32.6% |
Return vs Industry: ORGS underperformed the US Biotechs industry which returned 16.1% over the past year.
Return vs Market: ORGS underperformed the US Market which returned 31.6% over the past year.
Price Volatility
ORGS volatility | |
---|---|
ORGS Average Weekly Movement | 21.7% |
Biotechs Industry Average Movement | 9.8% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 15.8% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ORGS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ORGS's weekly volatility (22%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2008 | 146 | Vered Caplan | orgenesis.com |
Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals.
Orgenesis Inc. Fundamentals Summary
ORGS fundamental statistics | |
---|---|
Market cap | US$6.25m |
Earnings (TTM) | -US$34.41m |
Revenue (TTM) | US$899.00k |
7.0x
P/S Ratio-0.2x
P/E RatioIs ORGS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ORGS income statement (TTM) | |
---|---|
Revenue | US$899.00k |
Cost of Revenue | US$1.78m |
Gross Profit | -US$878.00k |
Other Expenses | US$33.53m |
Earnings | -US$34.41m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -6.66 |
Gross Margin | -97.66% |
Net Profit Margin | -3,827.81% |
Debt/Equity Ratio | -63.2% |
How did ORGS perform over the long term?
See historical performance and comparison